Sujentec's Antigen Rapid Diagnostic Kit 'Q4 Orders Surpass 3.5 Million'... "Additional 600,000 Orders from Russia and Others"

[Asia Economy Reporter Hyunseok Yoo] SuzenTech's global new orders for the 4th quarter 'Antigen Rapid Diagnostic Kits' have exceeded 3.5 million units (tests), marking the beginning of a significant increase in demand.

SuzenTech announced on the 25th that following a supply contract for 2 million antigen rapid diagnostic kits with Germany earlier this month, it has additionally secured orders for 600,000 units from Russia and Central Asia. As a result, the cumulative new orders for antigen rapid diagnostic kits in the 4th quarter have surpassed 3.5 million units.

Due to the faster-than-expected increase in demand for antigen rapid diagnostic kits amid the resurgence of COVID-19 in major countries worldwide, SuzenTech recently completed its application for Emergency Use Authorization (EUA) of its antigen rapid diagnostic kit with the U.S. FDA. In September, SuzenTech had already received FDA EUA for its antibody rapid diagnostic kit, externally validating its technology and accuracy.

A SuzenTech official stated, “With growing global concerns about a third COVID-19 pandemic wave, the adoption of rapid diagnostic kits is increasing, especially among health authorities in major countries worldwide. To prepare for the rising demand for antigen diagnostic kits, SuzenTech has obtained European CE certification and approvals from health authorities in several countries including Germany and Brazil, and has now applied for the U.S. FDA Emergency Use Authorization.”

He added, “In addition to antigen rapid diagnostics, we have a portfolio of diagnostic kits ranging from COVID-19 diagnosis to determining antibody formation after vaccination, including COVID-Influenza antigen simultaneous diagnostic kits and neutralizing antibody diagnostic kits, so product demand is expected to remain steady even after vaccine distribution.”

SuzenTech’s antigen rapid diagnostic kit tests for COVID-19 infection using nasopharyngeal swab specimens such as nasal mucus, similar to molecular diagnostic (PCR) methods. Results can be visually interpreted within 20 to 30 minutes, allowing immediate on-site classification of suspected patients.

Since the kit can be analyzed without expensive testing equipment or facilities, it is being used as an alternative to molecular diagnostics. Its use is expanding in countries with large numbers of confirmed cases or regions with relatively insufficient quarantine infrastructure as a substitute for molecular diagnostics.